Barclays Issues Positive Forecast for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price objective lifted by Barclays from $7.00 to $8.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have an equal weight rating on the biotechnology company’s stock.

Several other research analysts have also recently issued reports on BCRX. StockNews.com raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. JMP Securities upped their target price on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a report on Tuesday, August 6th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $14.67.

BioCryst Pharmaceuticals Stock Down 0.8 %

Shares of BCRX stock opened at $7.67 on Tuesday. The company has a 50 day moving average price of $7.78 and a 200-day moving average price of $6.98. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $8.88. The firm has a market capitalization of $1.59 billion, a PE ratio of -12.57 and a beta of 1.89.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.07). The company had revenue of $117.10 million for the quarter, compared to analysts’ expectations of $113.99 million. BioCryst Pharmaceuticals’s quarterly revenue was up 35.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.19) earnings per share. Analysts anticipate that BioCryst Pharmaceuticals will post -0.37 earnings per share for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Aigen Investment Management LP lifted its stake in shares of BioCryst Pharmaceuticals by 75.0% during the 3rd quarter. Aigen Investment Management LP now owns 28,661 shares of the biotechnology company’s stock valued at $218,000 after buying an additional 12,280 shares in the last quarter. Principal Financial Group Inc. raised its holdings in BioCryst Pharmaceuticals by 1,058.1% during the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock valued at $3,127,000 after acquiring an additional 375,890 shares during the period. Rice Hall James & Associates LLC lifted its position in shares of BioCryst Pharmaceuticals by 4.0% in the third quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock valued at $16,444,000 after acquiring an additional 84,102 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of BioCryst Pharmaceuticals by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 39,791 shares of the biotechnology company’s stock worth $302,000 after acquiring an additional 15,544 shares during the period. Finally, Semanteon Capital Management LP purchased a new stake in shares of BioCryst Pharmaceuticals during the third quarter worth about $1,137,000. 85.88% of the stock is currently owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.